This month’s guest is Dr. William Soliman. Will is the founder of The ACMA, the first and only global accreditation council for medical affairs professionals, he is also a seasoned media figure and thought leader in the biotech industry, with several years of leadership experience in the Pharma industry under his belt. Will has been instrumental in launching a variety of innovative platforms and expanding the role of medical affairs across the industry.
In this episode, Anne opens the show describing some future focused trends in the medical affairs field. She and Will speak on controversial drug pricing issues – such as, what does the election year mean for the industry from an innovation perspective? There is no doubt that we want to make drugs as affordable for as many people. However, the challenge comes in when a majority of the clinical trials fail. The solution to drug pricing may be thinking about more efficient and effective ways to design clinical trials. Machine learning and AI can come into play for a clinical trial designer. The V3 team discusses here.